Randomized evaluation of routine beta-blocker therapy after myocardial infarction quality of life (RQoL): design and rationale of a multicentre, prospective, randomized, open, blinded endpoint study

Author:

Humphries Sophia1ORCID,Mars Katarina2ORCID,Hofmann Robin2ORCID,Held Claes34ORCID,Olsson Erik M G5ORCID

Affiliation:

1. Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, 23100, Karolinska Institute , 141 83 Huddinge , Sweden

2. Department of Clinical Science and Education, Division of Cardiology, Karolinska Institute , Stockholm , Sweden

3. Department of Medical Sciences, Cardiology, Uppsala University , Uppsala , Sweden

4. Uppsala Clinical Research Center, Uppsala University , Uppsala , Sweden

5. Department of Women’s and Children’s Health, Uppsala University , Uppsala , Sweden

Abstract

Abstract Aims Most cases of acute myocardial infarction (MI) in Sweden are treated with long-term β-blocker therapy as secondary prevention. Case studies and patient reports have indicated negative effects of β-blockers including symptoms of depression, fatigue, sexual dysfunction, and general low mood, all related to reduced quality of life (QoL). To date, no recent large-scale, randomized trial has explored the effects of β-blockers on these factors. Methods and results The ongoing Randomized Evaluation of Decreased Usage of beta-bloCkErs after myocardial infarction (REDUCE): quality of life (RQoL) study is a multicentre, prospective, randomized pre-specified substudy aiming to evaluate the effects of β-blockers on self-reported measures of QoL. Following randomized allocation to long-term β-blocker or no β-blocker treatment, patients complete a total of six baseline measures pertaining to QoL, sexual functioning, and perceived side effects. Data collection is optionally carried out online through a unique and secure portal and repeated again at two follow-up time points. Recruitment began in July 2018. Data from the first 100 patients showed that at the first follow-up, 93% had completed the questionnaires, which decreased to 81% at the second follow-up. The method of digital data collection was utilized by over half of the patients recruited so far. Conclusion Data from the first 100 patients indicate success in terms of study design and recruitment. The RQoL substudy investigates the effects of β-blockers on self-reported measures of QoL in MI patients and will potentially contribute to the limited knowledge of QoL-related side effects reported in conjunction with β-blocker use. Clinical trial registration Eudra CT number, 2017-002336-17; Clinical trial.gov identifier, NCT03278509

Funder

Swedish Heart-Lung Foundation

Region Stockholm

Swedish Research Council

Publisher

Oxford University Press (OUP)

Reference45 articles.

1. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction;Norwegian Multicenter Study Group;N Engl J Med,1981

2. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial;Hjalmarson;Lancet,1981

3. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results;National Heart, Lung, and Blood Institute;JAMA,1982

4. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.;Eur Heart J,1985

5. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation;Collet;Eur Heart J,2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3